Cargando…

New‐onset vitiligo following COVID‐19 disease

BACKGROUND: Coronavirus disease 2019 (COVID‐19) disease and vaccines have been associated to various skin reactions, which are mostly similar amongst them. New onset of vitiligo and hypopigmentations have been described following COVID‐19 vaccination, but never after COVID‐19 infection. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzum, A., Micalizzi, C., Molle, M. F., Parodi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060013/
https://www.ncbi.nlm.nih.gov/pubmed/35665213
http://dx.doi.org/10.1002/ski2.86
_version_ 1784698428079472640
author Herzum, A.
Micalizzi, C.
Molle, M. F.
Parodi, A.
author_facet Herzum, A.
Micalizzi, C.
Molle, M. F.
Parodi, A.
author_sort Herzum, A.
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID‐19) disease and vaccines have been associated to various skin reactions, which are mostly similar amongst them. New onset of vitiligo and hypopigmentations have been described following COVID‐19 vaccination, but never after COVID‐19 infection. OBJECTIVES: We present the case of a 45‐year‐old woman, who developed vitiligo 2 weeks after COVID‐19 disease. Skin lesions stabilized after 1 month of initial spreading. RESULTS: Vitiligo is a relatively common acquired pigmentary disorder, possibly caused by a T CD8+ cell‐mediated autoimmune process, which may be enhanced after the immune activation of COVID‐19 disease. Molecular mimicry and bystander activation have been advocated as possible pathogenic mechanisms of vitiligo after COVID‐19 vaccination. The same mechanisms may also be involved as possible vitiligo triggers during COVID‐19 disease. CONCLUSIONS: Clinicians should be aware of this possible autoimmune cutaneous reaction to COVID‐19 disease.
format Online
Article
Text
id pubmed-9060013
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90600132022-06-04 New‐onset vitiligo following COVID‐19 disease Herzum, A. Micalizzi, C. Molle, M. F. Parodi, A. Skin Health Dis Letters to the Editor BACKGROUND: Coronavirus disease 2019 (COVID‐19) disease and vaccines have been associated to various skin reactions, which are mostly similar amongst them. New onset of vitiligo and hypopigmentations have been described following COVID‐19 vaccination, but never after COVID‐19 infection. OBJECTIVES: We present the case of a 45‐year‐old woman, who developed vitiligo 2 weeks after COVID‐19 disease. Skin lesions stabilized after 1 month of initial spreading. RESULTS: Vitiligo is a relatively common acquired pigmentary disorder, possibly caused by a T CD8+ cell‐mediated autoimmune process, which may be enhanced after the immune activation of COVID‐19 disease. Molecular mimicry and bystander activation have been advocated as possible pathogenic mechanisms of vitiligo after COVID‐19 vaccination. The same mechanisms may also be involved as possible vitiligo triggers during COVID‐19 disease. CONCLUSIONS: Clinicians should be aware of this possible autoimmune cutaneous reaction to COVID‐19 disease. John Wiley and Sons Inc. 2022-01-28 /pmc/articles/PMC9060013/ /pubmed/35665213 http://dx.doi.org/10.1002/ski2.86 Text en © 2021 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Herzum, A.
Micalizzi, C.
Molle, M. F.
Parodi, A.
New‐onset vitiligo following COVID‐19 disease
title New‐onset vitiligo following COVID‐19 disease
title_full New‐onset vitiligo following COVID‐19 disease
title_fullStr New‐onset vitiligo following COVID‐19 disease
title_full_unstemmed New‐onset vitiligo following COVID‐19 disease
title_short New‐onset vitiligo following COVID‐19 disease
title_sort new‐onset vitiligo following covid‐19 disease
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060013/
https://www.ncbi.nlm.nih.gov/pubmed/35665213
http://dx.doi.org/10.1002/ski2.86
work_keys_str_mv AT herzuma newonsetvitiligofollowingcovid19disease
AT micalizzic newonsetvitiligofollowingcovid19disease
AT mollemf newonsetvitiligofollowingcovid19disease
AT parodia newonsetvitiligofollowingcovid19disease